company background image
GLAXO logo

GlaxoSmithKline Pharmaceuticals NSEI:GLAXO Voorraadrapport

Laatste prijs

₹2.66k

Marktkapitalisatie

₹451.6b

7D

-4.5%

1Y

74.4%

Bijgewerkt

20 Oct, 2024

Gegevens

Financiële gegevens bedrijf +

GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Voorraadrapport

Marktkapitalisatie: ₹451.6b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

GLAXO Overzicht aandelen

GlaxoSmithKline Pharmaceuticals Limited produceert, distribueert en verhandelt farmaceutische producten in India en daarbuiten.

Over het bedrijf

GLAXO fundamentele analyse
Sneeuwvlok Score
Waardering1/6
Toekomstige groei5/6
Prestaties in het verleden3/6
Financiële gezondheid5/6
Dividenden3/6

Beloningen

De winst zal naar verwachting met 22.98% per jaar groeien
De winst is de afgelopen 5 jaar met 16.7% per jaar gegroeid

Risicoanalyse

Het dividend van 1.17% wordt niet goed gedekt door de winst of de vrije kasstromen

GlaxoSmithKline Pharmaceuticals Limited Concurrenten

Ipca Laboratories

NSEI:IPCALAB

₹418.6b

Ajanta Pharma

NSEI:AJANTPHARM

₹401.1b

Suven Pharmaceuticals

NSEI:SUVENPHAR

₹315.6b

Emcure Pharmaceuticals

NSEI:EMCURE

₹282.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GlaxoSmithKline Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers₹2,659.30
52 Week Hoogtepunt₹3,088.00
52 Week Laag₹1,385.05
Bèta0.22
11 maand verandering-2.11%
3 maanden verandering1.46%
1 Jaar Verandering74.35%
33 jaar verandering81.39%
5 jaar verandering71.44%
Verandering sinds IPO1,076.29%

Recent nieuws en updates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Rendement voor aandeelhouders

GLAXOIN PharmaceuticalsIN Markt
7D-4.5%-0.8%-0.9%
1Y74.4%60.3%39.7%

Rendement versus industrie: GLAXO overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 58.2 % opleverde.

Rendement versus markt: GLAXO overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 44.2 %.

Prijsvolatiliteit

Is GLAXO's price volatile compared to industry and market?
GLAXO volatility
GLAXO Average Weekly Movement4.2%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement6.2%
10% most volatile stocks in IN Market9.4%
10% least volatile stocks in IN Market3.9%

Stabiele aandelenkoers: GLAXO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van GLAXO is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
19243,211Bhushan Akshikarindia-pharma.gsk.com

GlaxoSmithKline Pharmaceuticals Limited produceert, distribueert en verhandelt farmaceutische producten in India en daarbuiten. Het bedrijf biedt vaccins aan, zoals Infanrix Hexa voor vaccinatie van zuigelingen tegen difterie, tetanus, pertussis, hepatitis B, poliomyelitis en ziekten veroorzaakt door Haemophilus influenzae type B; Synflorix voor actieve immunisatie van zuigelingen tegen pneumokokkenziekten en acute otitis media; Havrix voor actieve immunisatie tegen ziekten veroorzaakt door het hepatitis A-virus; Menveo voor de preventie van invasieve meningokokkenziekte; Boostrix voor immunisatie tegen difterie, tetanus en pertussis; Fluarix Tetra voor de preventie van influenza; Varilrix voor actieve immunisatie tegen varicella; en Shingrix voor de preventie van herpes zoster en postherpetische neuralgie. Het biedt ook gespecialiseerde geneesmiddelen, waaronder NUCALA voor ernstige eosinofiele astma, eosinofiele granulomatose met polyangiitis en hypereosinofiel syndroom; en TRELEGY ELLIPTA voor de behandeling van chronische obstructieve longziekte.

GlaxoSmithKline Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van GlaxoSmithKline Pharmaceuticals zich tot de beurswaarde?
GLAXO fundamentele statistieken
Marktkapitalisatie₹451.63b
Inkomsten(TTM)₹6.40b
Inkomsten(TTM)₹35.07b

70.6x

Koers/Winstverhouding

12.9x

P/S-verhouding

Is GLAXO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GLAXO resultatenrekening (TTM)
Inkomsten₹35.07b
Kosten van inkomsten₹13.54b
Brutowinst₹21.52b
Overige uitgaven₹15.12b
Inkomsten₹6.40b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 29, 2024

Winst per aandeel (EPS)37.78
Brutomarge61.38%
Nettowinstmarge18.25%
Schuld/Eigen Vermogen Verhouding1.1%

Hoe presteerde GLAXO op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.2%

Huidig dividendrendement

92%

Uitbetalingsratio